Adalimumab
These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023This product is YUFLYMA (adalimumab-aaty). YUFLYMA (adalimumab-aaty) is biosimilar* to HUMIRA (adalimumab).
c44365e9-d470-4e35-978d-8565a9e3471e
HUMAN PRESCRIPTION DRUG LABEL
Dec 8, 2023
CELLTRION USA, Inc.
DUNS: 116587378
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
adalimumab-aaty
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (2)
adalimumab-aaty
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (2)
adalimumab-aaty
Product Details
FDA regulatory identification and product classification information